Clinical trials: Stage D0 Prostate Cancer
Prostate Cancer
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a…
- Trial name
- NCT00514072
- Testing
- BCG vaccine, prostate cancer vaccine ONY-P1
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Kael-GemVax Co., Ltd.
Prostatic Neoplasms, Prostate Cancer
Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer
Background: Men who continue to have an elevated or rising prostate specific antigen (PSA) level after their primary prostate cancer treatment are at increased risk for their cancer to progress.
- Trial name
- NCT02362451
- Testing
- Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
This multi-center study will evaluate whether thalidomide can improve the effectiveness of the drugs leuprolide or goserelin in treating testosterone-dependent prostate cancer.
- Trial name
- NCT00004635
- Testing
- Thalidomide, leuprolide acetate, goserelin
- Where
- 9 sites in United States
- Volunteers
- 159 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Prostate Cancer
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
This randomized phase II trial is studying how well pazopanib hydrochloride works after leuprolide or goserelin in treating patients with relapsed prostate cancer.
- Trial name
- NCT00454571
- Testing
- pazopanib hydrochloride, leuprolide acetate, goserelin acetate
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer
Based on data supporting the use of cyclophosphamide and etoposide both as single agents in combination and a Phase I study showing acceptable toxicity with a chronic dosing regimen, we propose a Phase II clinical trial.
- Trial name
- NCT00176605
- Testing
- Etoposide, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Specific Antigens, Prostate Neoplasms
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Background: PSA (prostate specific antigen) is a protein found on normal and cancerous prostate cells. Levels of this protein are used to identify men who are at risk for prostate cancer and to monitor responses to treatment in…
- Trial name
- NCT00972309
- Testing
- T-cell receptor alternate reading frame protein (TARP) peptide vaccine, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer
The investigators are trying to find new methods to treat prostate cancer. The approach they investigators are taking is to try to enhance patients own immune response against the cancer.
- Trial name
- NCT00582140
- Testing
- pTVG-HP with rhGM-CSF
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Wisconsin, Madison
Prostatic Neoplasms, Neoplasms of Prostate
Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
Background: Few studies or literature are available about the long-term safety of repeated peptide vaccinations in people over a period of time. Long-term vaccination may be needed to control tumors.
- Conditions
- Prostatic Neoplasms, Neoplasms of Prostate, Prostate Cancer, Cancer Of Prostate
- Trial name
- NCT02362464
- Testing
- Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer
The current protocol will evaluate the safety of combining treatment with bicalutamide(Casodex) and CP-675,206 (anti-CTLA-4 monoclonal antibody) in patients with PSA-recurrent non-metastatic (stage D0) prostate cancer.
- Trial name
- NCT00702923
- Testing
- Bicalutamide and CP-675,206 (Tremelimumab), Bicalutamide, CP-675,206 (tremelimumab), Bicalutamide, CP-675,206
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison